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I. Introduction 
For many years there has been a presumption that 
women of childbearing age are to be automatically 
excluded from clinical studies. This approach has led to 
continued gaps in our scientific knowledge, as important 
information about metabolic activity and drug interactions 
in this group of subjects is not readily available. As a 
result, there is the possibility that drugs may be market-
ed with undetected side effects, or that the benefit of 
potential treatments may be delayed for women who may 
not have access to novel interventions as early in the 
research process as their male or infertile female coun-
terparts. 
In the past government regulations have emphasized 
the ethical principles of beneficence and respect for per-
sons in protecting subjects from risks and assuring their 
right NOT to participate in research studies.1 This has not 
changed. But we now also recognize the important ethi-
cal principle of justice with regard to who receives the 
benefits of clinical research and in assuring an individ-
ual's right TO participate in research. As a result, investi-
gators are now encouraged to use fertile women earlier 
in clinical trials. Such a change in thinking represents a 
major landmark. 
The new NIH requirements to include women as 
research subjects reflect the most recent changes in 
accepted standards of practice. In this article, we 
describe the experience of the National Institutes' of 
Health (NIH) in developing and implementing its policy 
regarding the representation of women as research sub-
jects, address the relevance of this policy to women of 
childbearing potential and pregnant women, and consid-
er the liability implications of their inclusion in research 
studies. 
II. Role of the NIH Office of Research on 
Women's Health 
The Office of Research on Women's Health (ORWH) 
was established in September 1990 within the Office of 
the Director, NIH. ORWH serves as a focal point for 
women's health research at NIH in setting and monitor-
ing policy, promoting and stimulating research, and 
enhancing scientific career development. ORWH works 
in partnership with the NIH research institutes, centers, 
and divisions to ensure that women's health research 
becomes an integral part of the scientific fabric at NIH 
and throughout the scientific community. ORWH has a 
threefold mandate: 
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• to strengthen and enhance research related to dis-
eases, disorders, and conditions that affect women 
and to ensure that research conducted and sup-
ported by NIH adequately addresses issues 
regarding women's health; 
• to ensure that women are appropriately represent-
ed in biomedical and behavioral research studies 
supported by NIH; and 
• to develop opportunities for recruitment, retention, 
re-entry, and advancement of women in biomed-
ical careers. 
Ill. NIH Policy 
It is the policy of NIH that women and members of 
minority groups and their subpopulations must be includ-
ed in all NIH-supported biomedical and behavioral 
research projects involving human subjects, unless a 
clear and compelling rationale and justification establish-
es to the satisfaction of the relevant Institute/Center 
Director that inclusion is inappropriate with respect to the 
health of the subjects or the purpose of the research.2 
This policy has evolved over the last decade. The 
Public Health Service assessed the representation of 
women in clinical trials in 1985,3 and NIH policy has 
addressed the inclusion of women and minority subjects 
in clinical research since 1986.4 The policy was strength-
ened in 1990 in response to weaknesses noted in the 
General Acqounting Office (GAO) report of that year.s 
The NIH Revitalization Act of 1993 (PL 103-43) gave 
existing policy the force of laws and stipulated some addi-
tional requirements, including a proscription against con-
sidering costs when evaluating research plans.7 The leg-
islation also delineated some general exceptions to poli-
cy. a 
The revised policy applies to all research involving 
human subjects.9 As described in the Guidelines, clinical 
research is defined broadly because of the need to 
obtain data about minorities and both genders early in 
the research process when hypotheses are being formu-
lated, baseline data are being collected, and various 
measurement instruments and intervention strategies 
are being developed. to Phase Ill clinical trials are to be 
designed and carried out in a manner that will provide for 
valid analysis of whether the variables being studied 
affect women or members of minority groups differently 
than other subjects in the trial.11 In all cases, the 
research study designs are evaluated prospectively by 
the NIH, as funding is contingent upon a satisfactory 
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inclusion plan that must meet the requirement before the 
study may commence. 12 
IV. Implementation of the NIH Policy 
One of the first steps in implementing the revised 
policy was to familiarize the staff of some 23 separate 
NIH institutes, centers, and divisions with the new 
requirements. This task was especially critical in light of 
findings by the General Accounting Office (GAO) in 1990. 
that the earlier policy had been inconsistently applied 
and had not been well communicated or understood 
within NIH or the research community.13 Thus, the 
changes mandated by the Revitalization Act provided an 
opportunity to reinforce the NIH commitment to inclusion 
by issuing renewed policy guidance, first to NIH staff and 
then to the entire scientific research community.1 4 
The NIH "Guidelines on the Inclusion of Women and 
Minorities as Subjects in Clinical Research" were pub-
lished as a Notice in the Federal Register on March 28, 
1994 (Guidelines). The Notice described revisions to pol-
icy made in response to the Revitalization Act and invit-
ed public comments during the first year of implementa-
tion.15 A variety of outreach activities were also initiated 
to explain the revised policy and to correct common mis-
understandings about its requirements. NIH staff gave 
presentations on the Guidelines at numerous profession-
al meetings and workshops, and NIH published a 
"Questions and Answers" document to provide more 
detailed policy guidance and address some of the more 
commonly asked questions about implementation of the 
Guidelines.16 
The Guidelines emphasize that the policy is intended 
to address gaps in scientific knowledge. A clinical study 
without appropriate numbers of women or minority sub-
jects may be scientifically flawed, as would one without 
an appropriate control group or one with serious method-
ological weaknesses. Thus, inclusion should be consid-
ered an issue of scientific merit. For this reason, it is the 
responsibility of peer reviewers to assess a project's 
inclusion plan as part of their evaluation of the research 
design. Under NIH review procedures, any application or 
proposal that is deemed unacceptable with regard to 
inclusion during initial review receives an administrative 
bar-to-funding, as does one found to be unacceptable 
with regard to the safeguarding of human subjects or the 
use of vertebrate laboratory animals. When this happens, 
the situation that caused the bar must be corrected 
before an NIH research institute or center may lift the bar 
and make an award.17 
V. Women of Childbearing Potential and 
Pregnant Women 
In September, 1992, ORWH commissioned the 
Institute of Medicine (10M) to establish a Committee on 
the Ethical and Legal Issues Relating to the Inclusion of 
Women in Clinical Studies (Committee). The Committee 
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was charged with examining the ethical and legal impli-
cations of policies that would broaden inclusion of 
women in clinical trials, including women of childbearing 
potential and pregnant women.1B The Committee's rec-
ommendations were finalized after passage of the 
Revitalization Act but before publication of the NIH 
Guidelines. Much of the Committee's recommendations 
were incorporated to varying degrees into NIH policy; 
however, the NIH Guidelines do not specifically address 
special rules for pregnant women. 
The Committee recognized the potential benefits of 
participation in research, such as access to new thera-
peutic interventions that might otherwise not be avail-
able. They emphasized respect for the autonomy of 
women to make decisions regarding their participation in 
clinical research studies and recommended that women 
who participate in research studies should be permitted 
to select voluntarily the contraceptive method of their 
choice where there are no relevant study-dependent, sci-
entific reasons for excluding certain contraceptives, such 
as drug interaction .19 The Committee recommended that 
federal policy should assure that neither women nor men 
of reproductive age should be excluded from participa-
tion in clinical studies.2o Both should have the opportuni-
ty to participate in the benefits and burdens of research. 
The potential or prospect of becoming pregnant during a 
study should not be used as a justification for precluding 
or limiting the participation of women of reproductive 
age.21 The Committee further recommended that preg-
nant women should also be presumed eligible for partic-
ipation in clinical studies.22 At the same time, it is impor-
tant to note that presuming pregnant women to be eligi-
ble is not the equivalent of advocating their active recruit-
ment into every clinical study, as there may be scientifi-
cally and medically valid reasons for excluding pregnant 
women from a particular study.23 
In moving from a paradigm of exclusion to one of 
inclusion, much sti)l needs to be done to overcome some 
of the barriers that have prevented women from full par-
ticipation in the past. For this reason ORWH has made 
some resources available to assist investigators in their 
outreach efforts, by providing support through adminis-
trative supplements to ongoing NIH grants. In July of 
1993, ORWH sponsored public hearings and a workshop 
entitled "Recruitment and Retention of Women in Clinical 
Studies," and subsequently published a summary of the 
issues and recommendations.24 The NIH also published 
an "Outreach Notebook" that offers some practical sug-
gestions for recruitment and retention of underrepresent-
ed subjects.2s 
VI. Liability Issues 
As a result of government policies on inclusion, the 
standard of practice for conducting clinical research is 
being changed. It is not entirely clear what effect this will 
have on future liability claims by women or their offspring 
who are injured as a result of their participation as 
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research subjects.26 Liability issues are not addressed in 
the NIH Guidelines. 
Medical researchers and pharmaceutical manufac-
turers share a fear that if a woman participating in 
research becomes pregnant and her fetus is harmed, 
they will be held liable.27 This fear is often the reason for 
the exclusion of women from clinical trials, despite a very 
low reported incidence of research injuries and few 
reported legal cases concerning such injuries.2B Fear of 
liability has not, however, operated to exclude men from 
participating in clinical trials, despite evidence that some 
fetal injury may be attributed to exposure of the father to 
toxic substances.29 Ironically, fear of liability has never 
operated as a rationale for the inclusion of women in clin-
ical research, even though there may be more legal 
precedent for liability for exclusion.3o 
The informed consent process is critical to assessing 
liability in research.31 Potential liability for injuries to 
women and men who participate in clinical research is 
unlikely, provided that informed consent to participate in 
the research is obtained in accordance with federal reg-
ulations and state tort law.32 Liability, then, turns on the 
"informed" nature of the woman's consent to participate 
in the research and whether she has been adequately 
warned about potential risks.331f the researcher has met 
the requisite standard of care by warning the woman of 
the potential risks of the trial in which she wishes to par-
ticipate, and she chooses to participate, it is unlikely that 
she will succeed in any subsequent negligence action for 
injuries that may occur as a result of her participation in 
the trial. 
Questions of liability more often focus on potential 
harm to the future offspring of women who participate in 
clinical trials. It is unclear in this context whether obtain-
ing the informed consent of the mother would be suffi-
cient to avoid liability for the injury to the offspring. The 
mother's consent would probably suffice when ,the 
research is of therapeutic value to the fetus,34 but it is not 
clear if this would be the case when the drug or inter-
vention was designed to be therapeutic for the mother 
only.35 To date there has been little case law establishing 
parameters for holding researchers or drug manufactur-
ers liable for injuries to the offspring of clinical trial par-
ticipants, but liability has been found when there was fail-
ure to obtain consent.36 It appears, then, that when there 
is no negligence and appropriate informed consent to 
participation in a clinical trial has been obtained, 
researchers and sponsors are unlikely to be held liable in 
tort for the inclusion of women in their studies.37 
Unlike speculation about liability for inclusion, legal 
precedent does exist that has based liability, in part, on 
the inadequate testing of a drug before it was released 
into the market.38 The evolution of public policy that 
establishes the importance of including women in clinical 
research has prompted several commentators to suggest 
that researchers and drug manufacturers should focus 
their concern on liability that results from the exclusion of 
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women from clinical research.39 Indeed, the thalidomide 
tragedy, perhaps the most notorious example of injury to 
offspring following the use of medication during pregnan-
cy, involved a pharmaceutical that had already been mar-
keted and was in widespread use. Thus, it is arguable 
that the failure to include women of childbearing potential 
in controlled clinical trials may result in the risk of injury 
to more individuals in less controlled and less monitored 
circumstances. It is also possible that a medical mal-
practice claim could result from the inappropriate appli-
cation of a treatment regimen that was developed 
through research in which only men were studied. Thus, 
in contrast to a research injury which results from being 
included in research, liability for exclusion results from 
the lack of data necessary to establish appropriate stan-
dards for the treatment of women. 
It is also important to note that unforeseen complica-
tions and unintended injuries, however tragic they may 
be, do not necessarily result in legal liability. 
Nevertheless, conscience compels that something be 
done to right the wrong. To a certain extent, the scientific 
community has already accepted responsibility for some 
adverse outcomes related to clinical research. Research 
protocols or informed consent documents may provide 
that if something goes wrong during the course of a study 
the subject will be treated at no expense. However, such 
provisions typically do not extend to compensation 
beyond immediate medical treatment, nor do they 
address injury to offspring. Clearly, more attention must 
be given to developing better remedies for potential 
injuries associated with research activities. These might 
include the possibility of a "no fault" approach for most 
research related injuries regardless of liability, while at 
the same time preserving the option of tort action for 
negligence. 
VII. Conclusion 
,. 
Questions concerning risk of liability are difficult to 
resolve, but there is growing consensus that the exclu-
sion of women from research studies may pose just as 
much risk of liability as their inclusion. Liability for inclu-
sion depends very much on the informed nature of the 
woman's consent to participate in the research. The actu-
al informed consent document should be viewed as more 
that just as a piece of paper to protect the sponsor. 
Instead, it is an important indicator demonstrating the 
quality of interaction that has taken place between inves-
tigator and subject throughout the research project. 
Perhaps the most cogent argument in favor of the 
NIH inclusion policy is the societal cost of continued gaps 
in scientific knowledge about important health problems 
that affect both women and men of diverse racial-ethnic 
groups.4o Gender differences must be appraised when 
generalizing results to entire populations,41 because a 
"one size fits all" standard of care is no longer accept-
able.42 
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